Project Grant R01HL176792
- The federal Project Grant award, titled "MicroRNAs in Airway Smooth Muscle Function and Asthma," was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837). The $616,814 award, with a start date of January 15, 2025 and a completion date of November 30, 2028, supports research at the President and Fellows of Harvard College (Harvard T.H. Chan School of Public Health) to investigate the role of microRNAs in regulating...
- The Project Grant award of $673,581 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a research project by Ochin, Inc. to assess disparities in asthma care between Latino and non-Hispanic white adults. The project aims to leverage a comprehensive dataset linking electronic health records to community-level social determinants of health data to evaluate factors underlying asthma care utilization disparities. The award runs from March 1, 2025...
- The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $189,000 Project Grant under CFDA #93.837 Cardiovascular Diseases Research program to the University of Colorado-Denver. The 2-year grant, with a period of performance from September 15, 2025 to August 31, 2027, will support research to investigate the role of outdoor air pollution and environmental allergens in driving treatment response in children with acute asthma...
- This $2,024,340 Project Grant was awarded on August 15, 2025 by the National Heart Lung and Blood Institute (NHLBI), part of the National Institutes of Health, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports a multi-year research effort at Boston Children's Hospital to optimize outcomes for hematopoietic stem cell transplantation (HCT), an essential treatment for high-risk non-malignant and malignant hematologic diseases. The research project...
- This federal Project Grant award of $805,921 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to integrate multi-trait, multi-ancestry, and multi-omic data from massive global biobanks to decipher the genetic mechanisms underlying respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma. The award, with a performance period from September 2025 to June 2030, will leverage data from over 2 million participants,...
- The National Heart, Lung, and Blood Institute (NHLBI), via the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $564,445 Project Grant to the University of Texas Health Science Center at Houston (UTHealth) to fund research on "Targeting Hypoxia-Inducible Factors (HIFs) for Heart and Lung Disease." The 6-year grant, starting on March 1, 2025 and ending on December 31, 2031, supports three complementary research projects focused on investigating the upstream regulation...
- This $2,456,717 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to exploit emerging ideas in G protein-coupled receptor biology and pharmacology to treat asthma. The award supports a highly collaborative research team at Thomas Jefferson University's Sidney Kimmel Medical College to pursue three key goals: 1) identify novel targets and targeting molecules involving G protein-coupled receptor...
- The University of New Mexico was awarded a $522,990 Project Grant under the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837). The grant, awarded on September 1, 2025, will support research to elucidate the mechanisms underlying the counter-regulation of allergic airway inflammation by regulating the responsiveness of Group 2 Innate Lymphoid Cells (ILC2s). The proposed studies aim to address the knowledge gap in...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $249,000.00 in funding to Brigham & Women's Hospital Inc. (a subsidiary of Partners Healthcare System) to develop methodologies for revealing the role of the blood microbiome in the gut-lung axis for asthma pathogenesis. The key products and services to be delivered include: A strain-resolved computational pipeline for reduced metagenomic sequencing to...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $771,750 to the Albert Einstein College of Medicine to conduct a cluster randomized controlled trial called "PRAGMATIC-S". The project aims to create an innovative interface between primary care and school-based programs to optimize the delivery of guideline-based asthma care to urban children with persistent or uncontrolled asthma. The award period runs...
This $1,511,779 Project Grant was awarded on September 25, 2025 by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant will support research at Harvard Pilgrim Health Care Inc. to identify causal mechanisms of metabolites in family-based association studies of childhood asthma among a Hispanic population in Costa Rica. The research aims to: 1) identify genetic associations between metabolites and lung function, 2) determine metabolomic determinants of lung function, and 3) examine the genetic effect on lung function as mediated by metabolites. This work leverages the Genetic Epidemiology of Asthma in Costa Rica (GACRS) cohort and will seek to replicate findings in the Childhood Asthma Management Program (CAMP). The research is expected to run from September 2025 through June 2027.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.5m | 9/22/25 |